000			02215 a2200589 4500
005			20250516044800.0
264		0	_c20120504
008			201205s 0 0 eng d
022			_a1432-1041
024	7		_a10.1007/s00228-011-1094-4 _2doi
040			_aNLM _beng _cNLM
100	1		_aAzuma, Junichi
245	0	0	_aThe relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. _h[electronic resource]
260			_bEuropean journal of clinical pharmacology _cJan 2012
300			_a29-37 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAntipsychotic Agents _xadverse effects
650	0	4	_aAripiprazole
650	0	4	_aBiotransformation
650	0	4	_aCytochrome P-450 CYP2D6 _xgenetics
650	0	4	_aCytochrome P-450 CYP2D6 Inhibitors
650	0	4	_aCytochrome P-450 CYP3A
650	0	4	_aCytochrome P-450 CYP3A Inhibitors
650	0	4	_aDrug Interactions
650	0	4	_aEnzyme Inhibitors _xadverse effects
650	0	4	_aFluvoxamine _xadverse effects
650	0	4	_aGenetic Association Studies
650	0	4	_aHalf-Life
650	0	4	_aHumans
650	0	4	_aJapan
650	0	4	_aMale
650	0	4	_aMetabolic Clearance Rate _xdrug effects
650	0	4	_aParoxetine _xadverse effects
650	0	4	_aPiperazines _xadverse effects
650	0	4	_aPolymorphism, Genetic
650	0	4	_aQuinolones _xadverse effects
650	0	4	_aSerotonin 5-HT2 Receptor Antagonists _xadverse effects
650	0	4	_aSelective Serotonin Reuptake Inhibitors _xadverse effects
650	0	4	_aYoung Adult
700	1		_aHasunuma, Tomoko
700	1		_aKubo, Masanori
700	1		_aMiyatake, Masaya
700	1		_aKoue, Toshiko
700	1		_aHigashi, Koushi
700	1		_aFujiwara, Tsutomu
700	1		_aKitahara, Sachiko
700	1		_aKatano, Tamiki
700	1		_aHara, Sumiko
773	0		_tEuropean journal of clinical pharmacology _gvol. 68 _gno. 1 _gp. 29-37
856	4	0	_uhttps://doi.org/10.1007/s00228-011-1094-4 _zAvailable from publisher's website
999			_c20991441 _d20991441